REGULATED INFORMATION
GHENT, Belgium, July 15, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that Euronext N.V. will introduce Spotlight Options on the shares of Ablynx (option trading symbol: ABY). The options will be available as of today on the derivatives market of Euronext Brussels.
Spotlight Options are a special segment on the Amsterdam and Brussels derivatives markets of Euronext, dedicated to the development of new option classes with a short maturity. Through a unique combination of Liquidity Provider support and dedicated promotion by Sponsoring Brokers, underlying assets with notable market events or activity will be put in the spotlight. The liquidity in these option classes will be supported by Susquehanna.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases in the areas of inflammation, haematology, oncology and pulmonology. The Company currently employs more than 300 people in its headquarters in Ghent, Belgium.
Dr Edwin Moses, Chief Executive Officer of Ablynx, commented:
"Ablynx has made tremendous progress since the initial public listing of the Company on Euronext Brussels in November 2007, both on an operational and financial level. Since its IPO, Ablynx has developed into one of the leading biopharmaceutical companies in Europe with more than 30 products in the R&D pipeline of which seven are in clinical development, partnerships with six major pharma companies, a strong cash position and a free float of 90%. We believe that the introduction of Spotlight Options will offer additional investment and trading possibilities, further increase the liquidity of our shares and improve the visibility of the Company in the financial markets."
Vincent Van Dessel, Chief Executive Officer of Euronext Brussels, added:
"We are pleased to announce the introduction of Spotlight Options for Ablynx on Euronext Brussels, providing institutional and retail investors with new investment opportunities. The Ablynx Spotlight Option class will benefit from the growing interest in Belgian options we have seen over the past year."
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® , a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has more than 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com .
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com
Euronext Brussels:
Jean-Yves Daxhelet
t: +32 2 213 13 03
e: jean-yves.daxhelet@interelgroup.com
pdf format of the press release http://hugin.info/137912/R/1822671/631201.pdf
HUG#1822671
